Zealand Pharma (CPSE:ZEAL) Could Be 43% Undervalued After Phase 2 Trial Success

What happened: Zealand Pharma (CPSE:ZEAL) said its Phase 2 ZUPREME-2 trial of petrelintide met the primary endpoint, showing weight loss and HbA1c improvements in adults with type 2 diabetes. Key numbers: Shares closed at DKK238. A narrative puts fair value at DKK416, about 43% undervalued. The stock fell 18.8% over 30 days and 52.2% over one year. Why it matters: The trial result has not lifted the shares, so the debate centers on whether the valuation offsets clinical and execution risk. The Roche alliance for petrelintide is cited as reducing commercialization risk. Market: -1.2% by next close ($233.90 on Oct 12), -49.9% YTD

Zealand Pharma (CPSE:ZEAL) said its Phase 2 ZUPREME-2 trial of petrelintide met the primary endpoint, showing weight loss and HbA1c improvements in adults with type 2 diabetes.

The trial result has not lifted the shares, so the debate centers on whether the valuation offsets clinical and execution risk. The Roche alliance for petrelintide is cited as reducing commercialization risk. Market: -1.2% by next close ($233.90 on Oct 12), -49.9% YTD